Fig. 3: H10ssF vaccination elicited antibodies against homologous H10 HA antigens. | npj Vaccines

Fig. 3: H10ssF vaccination elicited antibodies against homologous H10 HA antigens.

From: Phase 1 dose-escalation trial evaluating a group 2 influenza hemagglutinin stabilized stem nanoparticle vaccine

Fig. 3

Binding antibodies were assayed using H10 stabilized stem (H10ss, a, c) or full-length (H10FL, b, d) antigens by ECLIA. The AU/mL GM of the 60 mcg recipients’ binding antibodies (a, b) or fold change compared to baseline (c, d) are shown in black with 95% CI. Individual participants’ AU/mL are shown in red or blue lines based on their age group. In (c) and (d), the dashed line represents no fold change from baseline. Symbols in (a) and (b) indicate where the AU/mL GM values at week 2, 16, 18, or 40 after vaccination were significantly different (p < 0.001) from the AU/mL GM at day 0 or week 16.

Back to article page